New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: Switch studies data following agalsidase beta shortage

The update of the review on the effects of switching from agalsidase beta to alfa showed, in comparison to the previous review, an increased number of clinical events, a significant loss of renal function, and an increase in lyso Gb-3 levels, underscoring the importance of dose in the treatment of FD. Antonio Pisani received travel expenses and grants from Takeda Pharmaceuticals, Sanofi, Amicus, and Chiesi. The peer review history for this article is available at https://publons.com/publon/10.1111/cge.14266. Data sharing is not applicable to this article as no new data were created or analyzed in this study.